凯因科技：撤回培集成干扰素α-2注射液药品注册申请

Core Viewpoint - The company has received approval from the National Medical Products Administration to withdraw its drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) [1] Group 1 - The company has decided to withdraw the drug registration application based on a principle of prudence [1] - As a result of this decision, the company will fully recognize an asset impairment provision related to the project, which will reduce the company's total profit for the year 2025 by 111 million yuan [1]